Cala TAPS Therapy for Essential Tremor Patients Improves Outcomes in a New Randomized Controlled Trial

March 23, 2023–(BUSINESS WIRE)–Cala, the bioelectronic medicine leader setting a new standard of care for chronic disease, today announced meeting the primary endpoint on an interim analysis of a prospective, randomized, controlled study. This study, “RWE Study Utilizing the Cala Trio Device in Patients With Essential Tremor” (clinicaltrials.gov NCT05540626), demonstrated that adding TAPS therapy to the patient’s care plan improved outcomes.